I was recently queried by the Israeli Life Science Industry on my thoughts regarding trends in the global biotechnology industry as well as elements of specific interest to Israel. You can see my full interview at ILSI’s website.
I recently gave a talk on educating the next generation of biotechnology managers and founders at a biotechnology education workshop. My sense is that the traditional education paths are not ideal ways to prepare individuals to manage or start biotechnology companies, and I describe cases from Best Practices in Biotechnology Education and courses I have been involved with to illustrate how educational programs can better prepare students for these roles.
I’ve attached a copy of my presentation below.
I will be giving a talk on Educating the Next Generation of Biotechnology Founders and Managers at Pittcon in Orlando on March 1st.
The talk will be based on my observations in writing Building Biotechnology and editing Best Practices in Biotechnology Education, in addition to the teaching I’ve done on the topic. I’ll be posting my slides after the event, but for a preview you can see my recent editorial on continuing education in biotechnology in the Journal of Commercial Biotechnology.
Hope to meet some readers while I’m down there…
I’m giving a talk at Pittcon on biotechnology training this spring. As many readers know, I have been very active in biotechnology education through my books and the classes I teach. So, I’ve got a strong sense of the supply-side of biotechnology education and training, and the academic side of biotechnology education, but would like some more perspective on the industry side of biotechnology education and training.
So, I’d like to post an open question:
How do you train your new biotechnology employees?
I want to learn more about the training systems used to bring new hires, with either scientific or business backgrounds, up to speed on the business of biotechnology. What are the methods and tools you use? You may post your response in the comments below, or if you’d rather be off the record, feel free to contact me directly.
Moira Gunn’s Tech Nation interview of Jeremy Abbate and I on the Scientific American worldView project is now available at IT Conversations. For more details, you can also see our video interview and the worldView website.
The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 16, Issue 1
Editorial
Commentary
| Why data exclusivity is the new patent protection | PDF |
| Peter J Pitts | |
| Follow-on biologic drug competition – No need for new marketing exclusivities | PDF |
| Michael S Wroblewski, Elizabeth A Jex | |
Articles
Legal and Regulatory Updates
Book Reviews
I am honored to have been selected for the 2009 Kyoto Prize Journalism Fellowship, offered by Point Loma Nazarene University.
This fellowship will allow me to attend the Kyoto Prize Ceremony, laureate lectures and workshops, and associated functions. The Kyoto Prize is one of the world’s most prestigious awards given to those who have made outstanding lifetime achievements in technology, science, or the arts. This year’s laureates are:
Dr. Isamu Akasaki, Blue LED pioneer
Drs. Peter and Rosemary Grant, Evolutionary Biologists
Pierre Boulez, World-renowned composer, conductor
I am honored to have the opportunity to attend this prestigious event and to learn more about innovation in diverse disciplines.
The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 15, Issue 4
Editorial
Commentary
| The correlation between medical tourism and biotechnology | PDF |
| David G Vequist IV, Erika Valdez | |
| The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interview | PDF |
| William Bains | |
Articles
Legal and Regulatory Updates
| Legal and Regulatory Update | PDF |
| Gerry Kamstra, John Wilkinson | |
Book Reviews
My most recent editorial in the Journal of Commercial Biotechnology, “The impact of the global financial crisis on biotechnology development,” examines the response of governments around the world to their investments in biotechnology and healthcare innovation. It is a theme that I also raised in the Scientific American WorldVIEW. The bottom line is: despite economic hardships, given the direct health and indirect economic benefits of biotechnology research, will governments sustain, increase, or decrease their R&D budgets?
The impact of the global financial crisis on biotechnology development
The July 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 15, Issue 3
Editorial
Commentary
Articles
From the Classroom
Legal and Regulatory Updates
| Legal and regulatory update | PDF |
| John Wilkinson | |
Book Reviews
Prev